hotspot -WSS

hotspot

author：focus 2025-09-30 19:26:33 - browse：693

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Scientists inch closer to single

explore

focus

WSS

Readout Newsletter: Amylyx, Aurinia, and IQVIA

The high personal cost of affirmative action for Black doctors

Artificial intelligence use in health care faces greater scrutiny in 2024

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Breakthrough Alzheimer’s drugs are inaccessible in rural states

No plane should take off without an EpiPen onboard

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

In age of alternative facts, a scholarly course on calling out crap

Having children helps parents live longer, especially after age 80

Apple is now the first public company to be valued at $3 trillion

Artificial intelligence use in health care faces greater scrutiny in 2024

Alkermes shareholders re

Tome Biosciences co

As demand for Covid shots wanes, Moderna seeks its next success

5 important ways Henrietta Lacks changed medical science

Affirmative action in medical school literally saved lives

Eli Lilly reports tirzepatide MASH success during Q4 earnings

entertainment

Mitch McConnell episode has important public health takeaway

NIH launches clinical trials and new research office for long Covid

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Vertex non

Mega Millions pot grows to $1.25 billion after no winner

Pence says 'crackpot lawyers' told Trump what he wanted to hear

entertainment

explore

focus

Wikipedia